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Epigenetic alterations play an important role in the development of acute myeloid leukemia 
(AML) by silencing of genes that suppress leukemogenesis and differentiation. One of the 
key epigenetic changes in AML is gene silencing by DNA methylation. The importance 
of this alteration is illustrated by the induction of remissions in AML by 5-aza-2′-deoxy-
cytidine (5-AZA-CdR, decitabine), a potent inhibitor of DNA methylation. However, most 
patients induced into remission by 5-AZA-CdR will relapse, suggesting that a second 
agent should be sought to increase the efficacy of this epigenetic therapy. An interesting 
candidate for this purpose is 3-deazaneplanocin A (DZNep). This analog inhibits EZH2, a 
histone methyltransferase that trimethylates lysine 27 histone H3 (H3K27me3), a marker 
for gene silencing. This second epigenetic silencing mechanism also plays an important 
role in leukemogenesis as shown in preclinical studies where DZNep exhibits potent 
inhibition of colony formation by AML cells. We reported previously that 5-AZA-CdR 
in combination with DZNep exhibits a synergistic antineoplastic action against human 
HL-60 AML cells and the synergistic activation of several tumor suppressor genes. 
In this report, we showed that this combination also induced a synergistic activation 
of apoptosis in HL-60 cells. The synergistic antineoplastic action of 5-AZA-CdR plus 
DZNep was also observed on a second human myeloid leukemia cell line, AML-3. In 
addition, 5-AZA-CdR in combination with the specific inhibitors of EZH2, GSK-126, or 
GSK-343, also exhibited a synergistic antineoplastic action on both HL-60 and AML-3. 
The combined action of 5-AZA-CdR and DZNep on global gene expression in HL-60 
cells was investigated in greater depth using RNA sequencing analysis. We observed 
that this combination of epigenetic agents exhibited a synergistic activation of hundreds 
of genes. The synergistic activation of so many genes that suppress malignancy by 
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inTrODUcTiOn
Acute myeloid leukemia (AML) is the most common type of acute 
leukemia in adults (1). Despite the use of intensive chemotherapy 
and stem cell transplantation, AML is still fatal in approximately 
half of younger patients and in about 80% of elderly patients as 
a result of primary drug refractoriness, relapse, or treatment-
related mortality (2). Consequently, there is an urgent need to 
develop more specific and effective drugs to target leukemia-
specific alterations. Both genetic and epigenetic alterations play 
an important role in leukemogenesis (3). Epigenetics is defined 
as heritable changes in gene expression that is not caused by 
changes in the DNA sequence. These changes involve primarily 
DNA methylation, histone modifications, chromatin remodeling, 
and microRNAs.
A frequent epigenetic alteration that is observed in AML 
is aberrant DNA methylation (4–7). This event occurs by the 
conversion of cytosine to 5-methylcytosine by DNA methyl-
transferase in the promoter region of genes. The genes silenced 
by DNA methylation include tumor suppressors, transcription 
factors, apoptosis-related proteins, and regulators of myeloid 
differentiation (7). The importance of this epigenetic alteration 
is shown by the successful use of inhibitor of DNA methylation 
(5-aza-2′-deoxycytidine, decitabine, 5-AZA-CdR) to induce 
complete remissions in patients with AML (8–10). However, 
therapy of AML with 5-AZA-CdR is not curative (5, 11, 12).
It may be possible to increase the effectiveness of epigenetic 
therapy by using combinations of epigenetic agents. Chemical 
modifications of histones can also produce epigenetic changes in 
gene expression. The initial discovery that a histone deacetylase 
(HDAC) inhibitor enhanced gene expression of 5-AZA-CdR 
on leukemic cells (13) provided the rationale to investigate 
combinations of these two classes of epigenetic agents in clini-
cal trials. This approach was supported by preclinical studies 
that showed the synergistic interaction of 5-AZA-CdR and the 
HDAC inhibitor, sodium phenylbutyrate, on leukemic cells 
and in an animal model of leukemia (14). Interesting clinical 
responses were observed in AML patients treated with 5-AZA-
CdR and the HDAC inhibitor, valproic acid (5). However, these 
combinational chemotherapies did not improve the long-term 
outcome of AML (5), indicating that other approaches should 
be investigated.
An interesting target for epigenetic therapy is the histone 
methyltransferases EZH2 (15, 16). EZH2 is a subunit of the 
polycomb repressive complex 2. It plays a key role in embryonic 
development by suppression of the genes for differentiation so 
that embryonic stem cells maintain their “self-renewal” capacity 
and pluripotency (17). EZH2 trimethylates lysine 27 on histone 
3 (H3K27me3), a repressive marker for gene expression. Several 
studies have shown that EZH2 can function as an oncogene. 
Knockdown of EZH2 protein by RNA interference results in 
growth inhibition in several tumor models (18). EZH2 over-
expression has been reported in several types of cancer and is 
associated with adverse outcomes (19). The overexpression of 
EZH2 can be due to gene amplification (20) or a gain-in-function 
mutation (21).
In this report, we have selected 3-deazaneplanocin-A (DZNep) 
to target EZH2 and investigated its mechanism and capacity 
to enhance the antineoplastic action of 5-AZA-CdR. DZNep 
inhibits S-adenosylhomocysteine hydrolase, resulting in the 
cellular accumulation of S-adenosylhomocysteine, which acts as 
a competitive inhibitor of S-adenosyl-l-methionine, the methyl 
donor for methyltransferases (22). DZNep is a global inhibitor 
of methyltransferases (23). The preferential target of DZNep is 
EZH2 as shown by the reduction in the level of this enzyme and 
H3K27me3 after treatment of tumor cells with this analog (24). 
DZNep also induces apoptosis of tumor cells. DZNep activates 
developmental genes that are not silenced by DNA methylation 
(23, 24). Other EZH2 inhibitors that target the catalytic site of 
this enzyme are under investigation and show promising clinical 
activity against lymphoma (15, 16).
The rationale to use DZNep in combination with 5-AZA-
CdR for the therapy of AML is as follows: first, DZNep as a 
single agent shows activity against AML cells as indicated by the 
reduction in colony formation, induction of differentiation and 
increase survival of mice with AML (25). Second, some genes 
silenced by DNA methylation can escape gene activation by 
5-AZA-CdR if they contain the repressive marker H3K27me3 
(26). Third, genes that program differentiation and marked with 
H3K27me3 in embryonic stem cells have the highest prob-
ability to undergo DNA methylation in cancers (27). Fourth, a 
“cross-talk” exists between histone and DNA methylation. The 
trimethylation of H3K27 by EZH2 pre-marks genes for DNA 
methylation in cancer (28–31). These observations suggest 
that the interaction between DNA and histone methylation 
(H3K27me3) can promote leukemogenesis by silencing the 
genes that program differentiation. Targeting these two gene 
epigenetic silencing mechanisms using 5-AZA-CdR and 
DZNep has the potential to reverse this process and lead to 
effective therapy of AML (32).
We have reported previously that 5-AZA-CdR in combination 
with DZNep exhibits a synergistic antineoplastic action against 
AML cells and the reactivation of several genes that suppress 
leukemogenesis (33). In this report, in order to fully understand 
the chemotherapeutic potential of DZNep in combination with 
5-AZA-CdR for the treatment of AML, we have investigated in 
depth their activation of a large number of genes that can suppress 
leukemogenesis using RNA sequence analysis. In addition, we 
5-AZA-CdR plus DZNep suggests that epigenetic gene silencing by DNA and histone 
methylation plays a major role in leukemogenesis. Targeting DNA and histone methyla-
tion is a promising approach that merits clinical investigation for the treatment of AML.
Keywords: 5-aza-2-deoxycytidine, 3-deazaneplanocin a, myeloid leukemia, epigenetics, gene expression, 
chemotherapy
FigUre 1 | continued
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FigUre 1 | continued 
antineoplastic activity on myeloid leukemic cells after treatment with inhibitors of Dna methylation and eZh2. Survival of human HL-60 (a,B) and 
AML-3 (c,D) leukemic cells after treatment with 5-Aza-CdR alone or in combination with inhibitors of EZH2: DZNep, GSK-343, or GSK-126. The cells were treated 
with the indicated concentration of 5-AZA-CdR, and, at 24 h, the different EZH2 inhibitors were added. At 48 h, the leukemic cells were placed in soft agar medium 
for colony assay to measure survival. Analysis of induction of apoptosis at 72 h after drug treatment in HL-60 (e) and AML-3 (F) leukemic cells. The results are 
expressed as mean ± SEM, n = 3. 5-AZA-CdR (5-Aza), DZNep (D), GSK-343 (G), GSK-126 (G).
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demonstrated that their antineoplastic action was related to the 
induction of apoptosis and their synergistic antileukemic action 
was also observed with a second human myeloid leukemic cell 
line, AML-3 (34).
MaTerials anD MeThODs
cell lines and Materials
Human HL-60 myeloid leukemic cells were obtained from 
ATCC. The HL-60 cells were maintained in RPMI-1640-HEPES 
containing 10% fetal bovine serum (Wisent). Human OCI-
AML-3 (AML-3) myeloid leukemic cells were kindly provided 
by Mark Minden, Princess Margaret Hospital, Toronto. The 
AML-3 cells were maintained in alpha-MEM containing 10% 
fetal bovine serum (Wisent). 5-AZA-CdR was obtained from 
Dr. Alois Piskala, Institute of Organic Chemistry, Czechoslovak 
Academy of Sciences, Prague. DZNep was kindly provided by 
Dr. Victor E. Marquez, Chemical Biology Laboratory, National 
Cancer Institute, Frederick, MD, USA. 5-AZA-CdR and DZNep 
were dissolved in sterile phosphate buffer saline (PBS) pH 6.8 
solution. GSK-126 and GSK-343 were dissolved in DMSO and 
obtained from Xcess Biosciences Inc. or Structural Genomics 
Consortium (Toronto, ON, Canada), respectively.
antineoplastic assay
The in vitro antineoplastic activity of the drugs was evaluated by 
reduction of colony formation after drug treatment. The HL-60 
and AML-3 cells were treated with the indicated concentrations 
of drugs. At the end of drug treatment, a cell count was performed 
using the Beckmann Model Z Coulter Counter. For colony assays, 
the cells were placed in 0.3% soft agar medium containing 20% 
serum. The number of colonies (>500  cells) was counted after 
16–18 days of incubation. The cloning efficiency was in the range 
of 60%.
apoptosis analysis
Annexin V and propidium iodide (PI) staining were used to 
assess apoptosis and was determined using flow cytometry. The 
cells were treated as indicated. Twenty-four hours after the end 
of drug treatment, the cells were washed twice with cold PBS and 
resuspended in 1× Annexin V binding buffer (BD Biosciences 
Pharmingen). Then, 2  ×  105  cells were mixed gently with 
Annexin V-FITC (BD Biosciences Pharmingen) and PI solution 
(Sigma-Aldrich) and incubated for 15 min in the dark at room 
temperature. The cells were suspended in 1× Annexin V bind-
ing buffer, and staining was immediately quantified using a BD 
LSR Fortessa flow cytometer (San Jose, CA, USA) and analyzed 
with the BD DIVA (San Jose, CA, USA) software program. A 
minimum of 10,000 cells within the gated region was analyzed 
per measurement.
analysis of gene expression
Drug treatment of the HL-60 leukemic cells was performed as 
described previously (33). At 24  h after the end of drug treat-
ment, total RNA was isolated from HL-60 cells using the RNeasy 
Plus Mini kit (Qiagen). Quantity and integrity of total RNA 
were checked with a 2100 Bioanalyzer instrument (Agilent). All 
samples had an RNA integrity number >8. Paired-end RNASeq 
libraries were constructed using the TruSeq RNA Sample Prep 
kit v2 (Illumina). Quantification and quality control of RNASeq 
libraries were performed prior to sequencing using Illumina’s 
recommended protocols. Hundred base pairs of paired-end RNA 
sequencing were performed using eight samples per sequencing 
lane on the Illumina HiSeq 2000 platform at the Genome Quebec 
Innovation Centre, Montreal, Canada. Reads were assembled 
to a reference genome [hg19, European Hapmap (CEU) Major 
Allele release] using TopHat v1.3.2. The number of mismatches 
allowed per read was set to 2. PCR duplicates were removed 
using Picard-tools1 and non-properly paired and non-uniquely 
mapped reads were filtered out with SAMtools.2 Recalibration 
and local realignment was performed with GATK tools. BAM 
files were processed with Cufflinks to estimate isoform-level rela-
tive abundances and to perform differential expression analysis. 
Unsupervised analysis and hierarchical clustering was performed 
using JMP Genomics v6.0 (SAS Institute). The data are deposited 
in GEO (Gene Expression Omnibus) database under accession 
number GSE94344.
For comparative analysis of the expression of the transcripts, 
the genes were divided into different groups with similar bio-
logical functions (e.g., differentiation, senescence, apoptosis, 
etc.) using the gene lists of pathway-focused arrays from SA 
Biosciences.3 Gene function and comparison of expression of 
transcripts in normal human tissues was done using BioGPS (35) 
and Gene Card (36). The list of tumor suppressor genes (TSGs) 
and oncogenes was obtained from Zhao et al. (37) and UniProt 
Consortium (38).
ingenuity Pathway analysis
To elucidate the probable downstream effects on biological 
functions of the observed gene expression changes, we used the 
downstream effects analysis approach implemented in Ingenuity 
Pathway Analysis. The algorithm uses the Ingenuity Knowledge 
1 http://picard.sourceforge.net/.
2 http://samtools.sourceforge.net/.
3 www.sabiosciences.com.
FigUre 2 | rna sequence analysis of global gene expression in hl-60 leukemic cells after treatment with 5-aZa-cdr and/or DZnep. Heat map of 
expression of transcripts. HL-60 leukemic cells were treated with 100 nM 5-AZA-CdR (A). At 24 h 1,000 nM DZNep (D) was added to the medium. Drug removal at 
48 h. RNA isolation at 72 h as described in Section “Materials and Methods.” The pairwise comparisons were control (C) versus A; C versus D; and C versus A + D.
FigUre 3 | Downstream effects analysis enables prediction of the effect of gene expression changes in each treatment. (a) The heat map visualizes 
the downstream effects analysis results across the multiple treatments. The top clusters of diseases or biological functions that are predicted to increase or 
decrease in at least one treatment are shown. The disease or function scores are displayed using a gradient from dark blue to orange for activation z-scores. 
(B) The network of the top activated biological function in 5-AZA-CdR + DZNep treatment (apoptosis of leukemia cell lines) is shown. The edges are colored orange 
when leading to activation of the downstream node, blue when leading to its inhibition, and yellow if the findings underlying the relationship are inconsistent with the 
state of the downstream node. The predicted downstream effect of the observed expression changes on apoptosis is stronger pathway activation under the joint 
effect of 5-AZA-CdR and DZNep (activation z-score = 0.22).
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FigUre 4 | heat map expression of genes related to differentiation after 5-aZa-cdr and DZnep treatment of hl-60 myeloid leukemic cells. Drug 
treatment of the leukemic cells is described in Figure 2. C, control; A, 5-AZA-CdR; D, DZNep; A + D, 5-AZA-CdR plus DZNep.
TaBle 1 | relative expression for differentiation-related genes in hl-60 
leukemic cells after treatment with 5-aZa-cdr and DZnep.
Transcript genbank no. Fold change relative to control
5-aZa-cdr DZnep 5-aZa-
cdr + DZnep
CCR5 NM_001100168 16.3 11.7 71.7
NEFH NM_021076 36.3 3.9a 59.0
EMR1 NM_001974 21.4 20.3 41.6
EGR1 NM_001964 5.2 0.3 27.5
CXCR4 NM_001008540 3.0 0.7a 23.0
MYH11 NM_002474 8.8a 3.4a 21.1
ITGAM NM_001145808 6.2 17.9 19.4
PECAM1 NM_000442 5.3 4.3 19.2
PMEL NM_006928 10.6a 9.1a 19.0
CTSK NM_000396 3.2 1.1 18.9
COL10A1 NM_000493 0.1a 0.5a 17.0
SMTN NM_134269 8.6 6.6 16.9
SLC17A7 NM_020309 0.005a 0.04a 15.4
ITGAM NM_000632 5.2 12.5 14.7
PPARG NM_005037 0.001a 1.5a 13.8
CXCR4 NM_003467 1.8 0.3 13.3
TUBB3 NM_006086 3.1 0.04a 13.1
MAP2 NM_031845 5.7 5.2 9.4
ITGB4 NM_000213 0.02a 0.7a 9.0
CYP27B1 NM_000785 1.2 0.2a 5.0
TAGLN NM_001001522 0.2a 0.4a 3.5
CD79A NM_021601 4.9 1.0 3.3
aNot significant.
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Base and is based on a collection of experimental observations 
manually curated from the literature or other databases. Nodes 
and network edges from these data are used in combination with 
the observed gene expression changes to infer cause–effect rela-
tionships with a direction of the causal effect, i.e., either activating 
or inhibiting (39).
ethical considerations
This study was exempted from ethical approval by the Research 
Ethics Board of CHU Sainte-Justine since no patient samples 
were used.
resUlTs
antineoplastic action of 5-aZa-cdr Plus 
eZh2 inhibitors on Myeloid leukemic 
cells
We reported previously that the combination of 5-AZA-CdR and 
DZNep exhibited a synergistic antineoplastic effect on human 
HL-60 myeloid leukemic cells (33). In this report, we confirm 
that this synergy also takes place in human AML-3 myeloid 
leukemic cells as determined by a colony assay (Figures 1A,C). 
The AML-3 cells are more sensitive to 5-AZA-CdR than the 
HL-60 cells. For both cell lines, the combination of 5-AZA-CdR 
and DZNep showed a similar synergistic antileukemic effect. The 
antineoplastic action of DZNep on EZH2 is indirect and due to its 
TaBle 2 | relative expression for apoptosis-related genes in hl-60 
leukemic cells after treatment with 5-aZa-cdr and DZnep.
Transcript genbank no. Fold change relative to control
5-aZa-cdr DZnep 5-aZa-
cdr + DZnep
TNF NM_000594_6 13.6 17.2 45.2
BIK NM_001197 41.6 0.6 43.8
ERG NM_001136155 14.8 4.8 38.3
ETS1 NM_005238 13.7 6.8 37.0
BCL2A1 NM_004049 10.8 7.0 23.7
TNFSF10 NM_033994 12.1 8.0 22.9
BCL2A1 NM_001114735 3.3 6.8 19.7
FAS NM_152871 4.4 10.3 15.6
BCL2L1 NR_001191 0.3 3.1 13.3
CASP10 NM_032976 3.6 6.3 12.2
GADD45A NM_001199741 0.05 0.08 11.7
CFLAR NM_001202518 1.3 3.1 9.0
TNFSF10 NM_003810 2.2 0.8 6.0
CASP10 NM_001206542 0.9 2.6 6.0
CASP10 NM_032977 0.9 0.7 4.8
BNIP3L NM_004331 2.2 0.07 4.8
CASP10 NM_001206524 0.2 0.004 4.0
CASP10 NM_001230 0.2 0.5 3.3
CASP6 NM_001226 2.6 0.001 3.2
XIAP NR_037916 2.0 0.03 3.0
XIAP NM_001167 2.0 0.9 3.0
7
Momparler et al. Epigenetic Therapy of AML
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 19
potent inhibition of adenosyl homocysteine hydrolase (22). This 
action results in the accumulation of adenosyl homocysteine, a 
competitive inhibitor of S-adenosyl-l-methionine-dependent 
methylations. EZH2 uses S-adenosyl-l-methionine as the methyl 
donor to methylate H3K27. In support that the principle target 
for DZNep is EZH2, we compared its antileukemic action with 
the specific inhibitors of EZH2, GSK-126, and GSK-343 (40). We 
observed a similar synergy with all the combinations with these 
agents, suggesting that EZH2 is the primary target of DZNep 
(Figures 1B,D). However, DZNep was more active than GSK-343 
or GSK-126 (Figures 1A,C). We also investigated the induction 
of apoptosis by 5-AZA-CdR and DZNep on HL-60 and AML-3 
leukemic cells (Figures 1E,F). The combination showed a syner-
gistic induction of apoptosis for both cell lines.
effect of 5-aZa-cdr and DZnep  
on global gene expression in hl-60 
leukemic cells
The effect of 5-AZA-CdR and DZNep on global gene expres-
sion in HL-60 leukemic cells was determined by RNA sequence 
analysis (Figure 2). This figure shows the heat map displaying 
relative transcript abundances of 12,866 transcripts, each of 
which is differentially expressed (FDR 5%) at least in one of 
the pairwise comparisons of the four conditions. Relative 
to the control sample, 5-AZA-CdR alone showed a greater 
increase in the expression of transcripts as compared to DZNep. 
DZNep increased the activation of many cohorts of genes, but 
also showed a reduction in the expression of some genes. The 
combination of 5-AZA-CdR plus DZNep showed a synergistic 
increase in expression of hundreds of genes (Figure 2). Specific 
data on all of the genes are shown in Table S1 in Supplementary 
Material. In order to evaluate this very large data set, we used 
Ingenuity Pathway Analysis, an application for interpreting bio-
logical data and modeling complex networks (39). This analysis 
can identify the most relevant signaling pathways and has the 
potential to predict the downstream effects of the experimental 
chemotherapy. We performed a comparison analysis of the three 
pairwise contrasts (control versus 5-AZA-CdR, control versus 
DZNep, and control versus 5-AZA-CdR +  DZNep) from the 
database generated from HL-60 leukemic cells treated with these 
epigenetic agents. The analysis revealed the clusters of biological 
functions that show increased or decreased activity across the 
different contrasts and enabled visualization across the three 
contrasts (Figure 3A). In particular, this analysis revealed the top 
most synergistically affected biological functions are apoptosis 
(activation z-score =  0.22 in 5-AZA-CdR +  DZNep) and cell 
death (activation z-score =  0.18 in 5-AZA-CdR +  DZNep) of 
leukemia cell lines. Based on expression levels of all genes impli-
cated in these processes, both functions are predicted as highly 
activated under the synergistic treatment. The network of the top 
activated biological functions in 5-AZA-CdR + DZNep treatment 
(apoptosis of leukemia cell lines) is shown in Figure  3B. This 
conclusion was confirmed by our data on specific genes related 
to these phenomena as discussed in the section on apoptosis.
Below, we focused on the effect of treatment with 5-AZA-CdR 
and DZNep on gene expression levels of individual genes from 
several cohorts of genes based on their functional ontologies 
and in particular genes implicated in leukemogenesis, apoptosis 
and differentiation. Due to the relatively large number of genes 
whose expression was modulated by treatment with these epi-
genetic agents, we limited our focus to a subset of genes that are 
highly related to leukemogenesis (35–38). Nonetheless, Table S1 
in Supplementary Material contains the extended list of specific 
genes affected by the action of 5-AZA-CdR plus DZNep.
effect of 5-aZa-cdr and DZnep on 
expression of Differentiation genes
Since a block in differentiation is one of the hallmarks of AML, we 
investigated the action of this epigenetic therapy on the expres-
sion of genes that program differentiation. The transcriptional 
responses of genes related to differentiation after treatment with 
5-AZA-CdR plus DZNep in HL-60 leukemic cells are shown in 
Table 1 and Figure 4. Many of the genes involved in differentia-
tion were activated, some of which showed a remarkable syner-
gistic activation by this combination of epigenetic agents. The 
expression of these genes is observed primarily in differentiated 
tissues.4 NEFH gene codes for neurofilaments that are normally 
expressed in neuronal cells. MYH11 gene codes for myosin and 
exhibits high expression in smooth muscle. PMEL, a premela-
nosome gene, is expressed predominantly in the retina. These 
genes are important markers for cellular differentiation. These 
data indicate that 5-AZA-CdR plus DZNep turn on several dif-
ferentiation genes that are not related to the phenotype of myeloid 
leukemic cells and may contribute to the antileukemic action of 
these epigenetic agents. 5-AZA-CdR plus DZNep also exhibited 
4 http://biogps.org.
FigUre 5 | heat map expression of genes related to apoptosis after 5-aZa-cdr and DZnep treatment of hl-60 myeloid leukemic cells. Drug 
treatment of the leukemic cells is described in Figure 2. C, control; A, 5-AZA-CdR; D, DZNep; A + D, 5-AZA-CdR plus DZNep.
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a synergistic activation of many genes involved in development 
(Table S2 in Supplementary Material).
effect of 5-aZa-cdr and DZnep on 
expression of genes related to apoptosis 
and senescence
The individual gene data on the synergistic activation of apop-
tosis-related genes in HL-60 leukemic cells by 5-AZA-CdR and/
or DZNep are shown in Table 2 and Figure 5. The combination 
of 5-AZA-CdR and DZNep exhibited an increase of the expres-
sion of many genes that are positive regulators of apoptosis, such 
as TNFSF10, CASP6, CASP10, BNIP3L, and GADD45A (41). 
However, the combination also exhibited the activation of expres-
sion of several antiapoptotic genes, such as BCL2A1, BCL2L1, and 
XIAP (41). The action of 5-Aza-CdR and DZNep on the induction 
of apoptosis in HL-60 and AML-3 leukemic cells (Figures 1E,F) 
indicates activation of proapoptotic genes is the predominant 
action of these epigenetic agents and is clearly supported by our 
Ingenuity Pathway Analysis described above (Figure 3).
Cellular senescence is the phenomenon by which normal 
cells cease to divide after threshold limit of cell divisions. 
This phenomenon is known as “replicative senescence,” or 
the Hayflick limit (42). Suppression of senescence can favor 
the development of malignancy (43). The treatment of HL-60 
leukemic cells with 5-AZA-CdR and/or DZNep leads to the 
synergistic activation of many genes related to senescence 
(Table 3; Figure 6). Several of the activated genes are initia-
tors of senescence, including SPARC, EGR1, SERPINE1, and 
TP53BP1. The activation of these genes by 5-AZA-CdR and/
or DZNep may play an important role with respect to the 
antineoplastic action on HL-60 leukemic cells.
effect of 5-aZa-cdr and DZnep on 
expression of Tsgs
5-AZA-CdR and DZNep exhibited a synergistic activation of the 
expression of several important TSGs in HL-60 leukemic cells 
(Table  4). For example, CDKN2B (p15) is a cyclin-dependent 
kinase (CDK) inhibitor that inhibits cell growth by blocking G1 
progression into S phase. CDKN2B function as a TSG in AML 
is well established (44). Hypermethylation of CpG islands in 
its promoter region was shown to occur frequently (45). This 
epigenetic state is associated with reduced expression (46) and is 
an important molecular predictor of outcome. Loss of expression 
of CDKN2B accelerates the development of myeloid leukemia 
TaBle 3 | relative expression for senescence related genes in hl-60 
leukemic cells after treatment with 5-aZa-cdr and DZnep.
Transcript genbank no. Fold change relative to control
5-aZa-cdr DZnep 5-aZa-
cdr + DZnep
CD44 NM_001001391 317.4a 0.001a 488.9a
THBS1 NM_003246 1.9a 5.3a 65.9
TP53BP1 NM_005657 21.8 0.4a 47.0
ETS1 NM_005238 13.7 6.8 37.0
SERPINE1 NM_000602 2.4a 7.4a 34.2
EGR1 NM_001964 5.2 0.3 27.5
SPARC NM_003118 6.9 3.4a 19.2
IRF5 NM_032643 6.5 0.001a 17.4
ID1 NM_002165 16.9 1.3a 16.3
CDC25C NM_001790 8.6 0.003a 14.2
CHEK1 NM_001114122 2.4 8.5 12.0
IRF5 NM_001098629 3.2 1.4 10.9
CDKN2D NM_079421 3.9 0.07a 9.5
IRF7 NM_004029 3.1a 0.3a 9.5
IGFBP3 NM_000598 12.0a 0.001a 9.0
IRF7 NM_001572 2.5 0.7 8.6
CDK6 NM_001145306 0.8 2.5 6.4
CDKN2D NM_001800 1.5a 9.8a 6.0a
CCND1 NM_053056 0.3a 0.09a 5.6
IRF7 NM_004031 2.4 0.06a 4.8
CITED2 NM_006079 0.5 0.1 4.2
COL1A1 NM_000088 1.2 0.2a 3.8
ING1 NM_198218 0.9a 0.4a 3.7
MAPK14 NM_139014 0.8a 0.8a 3.6
aNot significant.
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DiscUssiOn
Epigenetic alterations that silence gene expression play an 
important role in the development of AML. Aberrant DNA 
methylation that silences genes which suppress leukemogenesis 
occurs frequently in AML (45). The importance of this epigenetic 
modification is illustrated by the clinical activity of the potent 
inhibitor of DNA methylation, 5-AZA-CdR, for the treatment 
of AML (9). However, 5-AZA-CdR therapy of AML for most 
patients is not curative, and new approaches are needed to 
optimize the treatment of AML with this epigenetic drug. One 
factor that may limit the clinical effectiveness of 5-AZA-CdR 
for the treatment of AML is that this cytosine nucleoside analog 
has difficulty to activate DNA-methylated genes that contain the 
histone repressive marker, H3K27me3 (26). This latter epigenetic 
alteration is catalyzed by EZH2 methyltransferase (53). DZNep, 
a potent inhibitor of EZH2, shows remarkable antineoplastic 
activity against AML cells (25). This observation provided a 
good rationale to use DZNep in combination with 5-AZA-CdR. 
We reported previously that inhibition of DNA methylation 
and EZH2 by 5-AZA-CdR and DZNep, respectively, exhibits a 
synergistic antineoplastic effect on HL-60 AML cells (33). We 
confirm in this study that the synergistic antineoplastic action of 
this combination is also observed with a second human myeloid 
leukemic cell line, AML-3. DZNep is a global inhibitor of histone 
methylation (23). GSK-126 and GSK-343, specific inhibitors of 
EZH2, exhibit a similar synergy in combination with 5-AZA-CdR 
as observed with DZNep. This observation supports that EZH2 is 
the preferential target for DZNep.
In a previous study using real-time PCR and microarray 
analysis, we observed that 5-AZA-CdR plus DZNep exhibited 
a synergistic activation of several TSGs in HL-60 leukemic 
cells (33). In this report, we investigated the action of this 
combination on gene expression in greater depth using RNA 
sequence analysis. Each methodology has particular methodo-
logically related detection biases and limitations, which could 
explain why some differences were observed between our 
previous microarray and RT-PCR results and the present RNA 
sequencing with respect to the expression of several of genes 
that were detected. Ideally for genes of interest, our RNASeq 
data would have been confirmed using a second methodology, 
but there was insufficient mRNA available to do this. However, 
we nevertheless observed a synergistic increase in expression 
of hundreds of different transcripts by this combination of 
epigenetic agents. This synergistic effect of 5-AZA-CdR plus 
DZNep is highly consistent with the antineoplastic action of 
this combination. Epigenetic activation of specific genes that 
program apoptosis are likely one of the major contributors to 
the antileukemic action of 5-AZA-CdR and DZNep (Figure 5). 
This is shown by a synergistic activation of several genes that 
induce apoptosis, such as CASP6 (Table 2). These gene expres-
sion data are also supported by the synergistic induction of 
apoptosis in the HL-60 leukemic cells by 5-AZA-CdR plus 
DZNep (Figures 1E,F).
The genes that program differentiation also merit serious 
consideration (Table  1; Figure  4). These genes show a high 
frequency of DNA methylation in many different types of cancer 
in transgenic mice (47). Another important TSG is CDKN1A 
(p21), the expression of which is correlated with cell-cycle arrest 
that precedes terminal differentiation in a variety of tissues (48). 
CDKN1A is also implicated in regulation of cell growth and 
cell response to DNA damage. In response to DNA damage, 
p53 induces CDKN1A expression, which is responsible for the 
cell-cycle arrest at the G1 checkpoint (48). Other TSGs show 
similar patterns. We observed massive overexpression of EGR1, 
a zinc finger protein that functions as a transcriptional regulator. 
Overexpression of EGR1, one of the derepressed genes in EZH2-
deficient leukemic cells, promoted profoundly the differentiation 
of AML cells (49). EXT1 (Exostosin-1), a glycosyltransferase, is 
another highly upregulated gene whose expression is reduced 
in human cancer cells by DNA methylation (50). Introduction 
of a functional EXT1 gene into cancer cell lines induces tumor-
suppressor-like features, such as reduced colony formation and 
tumor growth in nude mouse xenografts. DNA methylation of 
EXT1 is common in leukemia (50). HES1, a helix-loop transcrip-
tional repressor, is frequently downregulated in AML (51). HES1 
activation suppresses proliferation of leukemia cells in AML. 
These results demonstrate the TSG role of HES1 in AML. Finally, 
we observe upregulation of RUNX3 a runt-domain transcriptional 
factor. The hypermethylation of this gene is frequent in AML cell 
lines (52). Relapse-free survival of AML patients without RUNX3 
methylation was significantly better than that of methylated 
cases. These results support the idea that RUNX3 silencing is an 
important event in AML.
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FigUre 6 | heat map expression of genes related to senescence after 5-aZa-cdr and DZnep treatment of hl-60 myeloid leukemic cells. Drug 
treatment of the leukemic cells is described in Figure 2. C, control; A, 5-AZA-CdR; D, DZNep; A + D, 5-AZA-CdR plus DZNep.
and contain high levels of the H3K27me3 marker in adult stem/
progenitor cells (27). The synergistic activation of so many genes 
that program differentiation by 5-AZA-CdR plus DZNep sup-
port the hypothesis that gene silencing by DNA methylation and 
H3K27me3 plays a very important role in the leukemogenesis 
of AML. Since these epigenetic alterations in the leukemic cells 
resemble that of embryonic stem cells (54, 55), it is possible that 
this epigenetic therapy has the potential to target leukemic stem 
cells (32). This interesting hypothesis merits further investiga-
tion. This may be a one of the key mechanisms that explains the 
block in differentiation that is a hallmark of AML. The synergistic 
activation of genes that promote senescence may also contribute 
to its antileukemic action of this combination of these epigenetic 
agents.
It is of interest to investigate if the antineoplastic synergy 
that we observed between 5-AZA-CdR and DZNep on myeloid 
leukemic cells also occurs in tumors. In this regard, we reported 
recently that 5-AZA-CdR and DZNep show a synergistic anti-
neoplastic action against human lung carcinoma cells (56). The 
synergistic interaction between these two epigenetic agents was 
also observed against rhabdoid tumor cells (57). 5-AZA-CdR in 
combination with the EZH2 inhibitor, GSK-126, inhibited the 
in  vivo growth of a prostate tumor xenograft more effectively 
than treatment with 5-AZA-CdR alone (58). These observations 
suggest that the reversal of gene silencing by DNA and histone 
methylation using epigenetic agents may also be an effective 
therapy for tumors.
cOnclUsiOn
Our data support the hypothesis that the antileukemic activity of 
5-AZA-CdR plus DZNep results from the summation of the acti-
vation of different cohorts of genes that suppress leukemogenesis 
by different mechanisms, including the induction of apoptosis, 
differentiation, development, and senescence. However, since so 
many genes in these different categories are activated, it is not 
possible to define the precise mechanisms involved. The genes 
that program differentiation may play a prominent role in this 
process since the block in differentiation is one of the hallmarks 
of AML. In order to accomplish this, leukemic stem cells have 
to “turn off ” the genes that program differentiation by DNA and 
H3K27 methylation. The synergistic activation of so many genes 
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